Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
about
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazoneElevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.
P2860
Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Combined pioglitazone and metf ...... s: results from a pilot study.
@en
Combined pioglitazone and metf ...... s: results from a pilot study.
@nl
type
label
Combined pioglitazone and metf ...... s: results from a pilot study.
@en
Combined pioglitazone and metf ...... s: results from a pilot study.
@nl
prefLabel
Combined pioglitazone and metf ...... s: results from a pilot study.
@en
Combined pioglitazone and metf ...... s: results from a pilot study.
@nl
P2093
P2860
P1476
Combined pioglitazone and metf ...... s: results from a pilot study.
@en
P2093
Benedikt Kerschgens
Cloth Hohberg
Gerhard Dikta
Iris Kleine
Petra B Musholt
Silvia Hehenwarter
Thomas Forst
Thomas Schöndorf
Winfried Fuchs
P2860
P304
P356
10.1177/193229680900300626
P577
2009-11-01T00:00:00Z